A Phase 2 interventional study of Ketamine in Rett Syndrome, sponsored by Rett Syndrome Research Trust. Completed at 7 sites in United States. Open to female participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-05-28.
Sponsored by Rett Syndrome Research Trust · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Rett Syndrome with a site in United States — 11 open to participants now, 21 under way, 5 of them phase 3. Rett Syndrome · United States.
Among the 55 studies in Rett Syndrome with a site in United States, this one is the 21st largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2019, is one of 10 in phase 2, and was the 23rd registered.
96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.
Browse Rett Syndrome studies →11 of the 55 studies in Rett Syndrome with a site in United States are open now. Recruiting first, the newest first:
Biomed Industries, Inc. · Sites in United States, Australia
Ages 5–20 · Women only
UCB BIOSCIENCES, Inc. · Sites in United States, Belgium, China and 10 more countries
Ages 5–35
University of Rochester · Sites in United States
Ages 2+ · Healthy volunteers
University of Minnesota · Sites in United States
Ages 18–99
Ionis Pharmaceuticals, Inc. · Sites in United States, Austria, Canada and 2 more countries
Ages 2–65 · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.
This study: 6 Years to 12 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 14
First in 2004; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 30 across 64 interventional studies indexed under Rett Syndrome.
Median enrollment 32 across the 34 interventional studies, 146 across the 21 observational. Of the 31 that completed or were terminated, 14 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 55 have an industry lead sponsor. The 10 most frequent:
Rett Syndrome Research Trust is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Rett Syndrome Research Trust has 5 studies filed under Rett Syndrome — fewer than ten, so there is no comparison to draw.
10 of the studies in Rett Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06840496Phase 3Biomed Industries, Inc.To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome | 2027-09-30 |
| NCT06338267Rett Syndrome Research TrustValidating Innovative Biosensors for Rett Autonomic Symptom Tracking | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06139172Rush University Medical CenterWeb Intervention for Parents of Youth With Genetic Syndromes (WINGS) | 2026-12 |
| NCT05012475Georgetown UniversityMeasuring Impact of Computer Gaming on Arm Use in Rett Syndrome | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 55 studies in Rett Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This 2 cohort, sequential, ascending dose study will assess the safety, tolerability and efficacy of oral ketamine dosed in a single 5-day BID regimen in addition to placebo, in a 4-week cross-over design in patients with Rett Syndrome. Approximately 12 patients per cohort are anticipated to participate for approximately 8-10 weeks at approximately 7 US study centers.
This study is designed to assess oral ketamine for the treatment of Rett Syndrome and consists of up to 4 ascending dose cohorts, each assessing 1 dose level of ketamine vs placebo. Patients will receive in either order, a 5-day BID regimen of both placebo and the cohort-specified dose level of oral ketamine. Patients may only participate in 1 cohort. Safety and tolerability will be assessed via patient disposition, vital signs, physical examination, adverse events and concomitant medication use. Efficacy will be assessed via physician and caregiver questionnaires and assessments, and continuous, wearable, at-home biosensor data collection. An independent safety committee will review safety data from each cohort to determine if the subsequent ascending dose cohort is warranted. A total of 12 patients per cohort is anticipated at approximately 7 sites. The screening period will last between 2 and 4 weeks, the cross-over treatment period will last 4 weeks, and the safety follow-up period will last 2 weeks. Total patient participation is approximately 8-10 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo
Drug: Ketamine
ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo
Drug: Ketamine
oral ketamine dosed twice daily for 5 days
Also known as: Ketalar
Dose-Limiting Adverse Events
The Number of Participants with Treatment-emergent adverse events on ketamine compared to placebo will be summarized
Time frame: 6 weeks
Continuous Biosensor Data
2 different non-invasive, wearable devices will be used in the study to determine changes in physiologic measures for the patient in the home environment. Biosensors will be worn continuously during the screening and treatment period to measure activity, sleep, position, heart rate, and breathing.
Time frame: 6-8 weeks
Clinical Global Impression of Improvement
Clinicians will use a 7 point Likert Scale to rate change from baseline symptom severity by addressing the question, "Compared to the patient's condition of Rett syndrome prior to treatment initiation at baseline, the patient's current condition is: 1 very much improved, 2 much improved, 3 minimally improved, 4 no change, 5 minimally worse, 6 much worse, 7 very much worse. No change would be scored a 0, while improvement would be scored at -1, -2, or -3 and worsening would be scored +1, +2 or +3, depending on the degree of perceived change. Negative change indicates improvement while positive change indicates worsening
Time frame: 4 weeks
Motor Behavioral Assessment
a 37-item questionnaire for clinicians to evaluate current behavioral/social, orofacial/respiratory, and motor/physical symptoms. Each item is rated either 0 (normal or never), 1 (mild or rare), 2 (moderate or occasional), 3 (marked or frequent), 4 (very severe or constant), where higher numbers indicate higher severity. Each subscale is summed for a subscale score, while the total score is a sum of the subscale scores. The behavioral/social subscale score may range from 0 to 64; the orofacial/respiratory subscale may range from 0 to 28, and motor/physical subscale may range from 0 to 56. Total score may range from 0 to 148.
Time frame: 4 weeks
Clinician Domain Likert Scale
an 8 category (domain) questionnaire to assess current hand function, walking, verbal and non-verbal communication, comprehension, attention, behavior problems, and mood by considering the question, "Considering your experience with the patient at this visit, please rate the level of function in each category". Each domain will be rated on a 7 point Likert Scale where the clinician will select 1 of 7 choices: 1 normal, 2 borderline abnormal, 3 mildly abnormal, 4 moderately abnormal, 5 markedly abnormal, 6 severely abnormal, 7 extremely abnormal. Lower values indicate lesser severity while higher values indicate higher severity.
Time frame: 4 weeks
Rett Syndrome Behaviour Questionnaire
a 45-item questionnaire for clinicians to evaluate current behavior and emotional features. Each item is rated either 0 (not true or not done), 1 (somewhat or sometimes true) and 2 (very true), where higher numbers indicate higher severity. Total score is summed and may range from 0 to 90.
Time frame: 4 weeks
Parent Domain Likert Scale
a 9 category (domain) questionnaire to assess current hand function, walking, verbal and non-verbal communication, comprehension, attention, behavior problems, mood, and seizure activity, by considering the question, "Considering your experience with your child over the past 7 days, please rate your child's level of function in each category". Each domain will be rated on a 7 point Likert Scale where the parent/caregiver will select 1 of 7 choices: 1 normal, 2 borderline abnormal, 3 mildly abnormal, 4 moderately abnormal, 5 markedly abnormal, 6 severely abnormal, 7 extremely abnormal. Lower values indicate lesser severity while higher values indicate higher severity.
Time frame: 4 weeks
Children's Sleep Habits Questionnaire
a 35-item questionnaire for parents to evaluate current sleep and common sleep problems. The parent/caregiver will rate each item as 1 (rarely), 2 (sometimes), or 3 (usually), where higher scores indicate higher severity. The parent/caregiver will also indicate if the item is a problem or not. A total score of the sum of each item and 8 subscale scores (bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep disordered breathing, and daytime sleepiness) are possible. Total scores between 0 and 70 are possible, where higher scores indicate more sleep problems.
Time frame: 4 weeks
Rett Caregiver Burden Inventory Assessment
a 26-item questionnaire for parents to evaluate the burden of care on their quality of life. The parent/caregiver will rate each item as 0 (never), 1 (rarely), 2 (sometimes), 3 (quite frequently), or 4 (nearly always) where higher scores indicate higher severity. Total scores between 0 and 104 are possible, where higher scores indicate more caregiver burden.
Time frame: 4 weeks
EEG Signature
ketamine EEG alpha, beta, gamma, delta and theta waveform signatures compared to placebo to indicate target engagement
Time frame: Day 1, Day 15
The study was conducted at 7 sites in the US with active participants between 12Mar2019 and 22Nov2021.
| Milestone | 0.75 mg/kg (Placebo First, Then 0.75 mg/kg Ketamine) | 0.75 mg/kg (0.75 mg/kg Ketamine First, Then Placebo) | 1.5 mg/kg (Placebo First, Then 1.5 mg/kg Ketamine) | 1.5 mg/kg (1.5 mg/kg Ketamine First, Then Placebo) |
|---|---|---|---|---|
| Started | 5 | 6 | 6 | 6 |
| Completed | 5 | 6 | 5 | 6 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
The Number of Participants with Treatment-emergent adverse events on ketamine compared to placebo will be summarized
| Participants | 0.75 mg/kg Ketamine | 0.75 mg/kg Placebo | 1.5 mg/kg Ketamine | 1.5 mg/kg Placebo |
|---|---|---|---|---|
| TEAEs | 2 | 4 | 6 | 3 |
| SAEs | 0 | 0 | 0 | 0 |
| AEs leading to discontinuation | 0 | 0 | 1 | 0 |
| AEs leading to dose interruption | 0 | 0 | 0 | 0 |
| No TEAEs reported | 9 | 7 | 5 | 9 |
2 different non-invasive, wearable devices will be used in the study to determine changes in physiologic measures for the patient in the home environment. Biosensors will be worn continuously during the screening and treatment period to measure activity, sleep, position, heart rate, and breathing.
Results for this outcome have not been posted.
Clinicians will use a 7 point Likert Scale to rate change from baseline symptom severity by addressing the question, "Compared to the patient's condition of Rett syndrome prior to treatment initiation at baseline, the patient's current condition is: 1 very much improved, 2 much improved, 3 minimally improved, 4 no change, 5 minimally worse, 6 much worse, 7 very much worse. No change would be scored a 0, while improvement would be scored at -1, -2, or -3 and worsening would be scored +1, +2 or +3, depending on the degree of perceived change. Negative change indicates improvement while positive change indicates worsening
Results for this outcome have not been posted.
a 37-item questionnaire for clinicians to evaluate current behavioral/social, orofacial/respiratory, and motor/physical symptoms. Each item is rated either 0 (normal or never), 1 (mild or rare), 2 (moderate or occasional), 3 (marked or frequent), 4 (very severe or constant), where higher numbers indicate higher severity. Each subscale is summed for a subscale score, while the total score is a sum of the subscale scores. The behavioral/social subscale score may range from 0 to 64; the orofacial/respiratory subscale may range from 0 to 28, and motor/physical subscale may range from 0 to 56. Total score may range from 0 to 148.
Results for this outcome have not been posted.
an 8 category (domain) questionnaire to assess current hand function, walking, verbal and non-verbal communication, comprehension, attention, behavior problems, and mood by considering the question, "Considering your experience with the patient at this visit, please rate the level of function in each category". Each domain will be rated on a 7 point Likert Scale where the clinician will select 1 of 7 choices: 1 normal, 2 borderline abnormal, 3 mildly abnormal, 4 moderately abnormal, 5 markedly abnormal, 6 severely abnormal, 7 extremely abnormal. Lower values indicate lesser severity while higher values indicate higher severity.
Results for this outcome have not been posted.
a 45-item questionnaire for clinicians to evaluate current behavior and emotional features. Each item is rated either 0 (not true or not done), 1 (somewhat or sometimes true) and 2 (very true), where higher numbers indicate higher severity. Total score is summed and may range from 0 to 90.
Results for this outcome have not been posted.
a 9 category (domain) questionnaire to assess current hand function, walking, verbal and non-verbal communication, comprehension, attention, behavior problems, mood, and seizure activity, by considering the question, "Considering your experience with your child over the past 7 days, please rate your child's level of function in each category". Each domain will be rated on a 7 point Likert Scale where the parent/caregiver will select 1 of 7 choices: 1 normal, 2 borderline abnormal, 3 mildly abnormal, 4 moderately abnormal, 5 markedly abnormal, 6 severely abnormal, 7 extremely abnormal. Lower values indicate lesser severity while higher values indicate higher severity.
Results for this outcome have not been posted.
a 35-item questionnaire for parents to evaluate current sleep and common sleep problems. The parent/caregiver will rate each item as 1 (rarely), 2 (sometimes), or 3 (usually), where higher scores indicate higher severity. The parent/caregiver will also indicate if the item is a problem or not. A total score of the sum of each item and 8 subscale scores (bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep disordered breathing, and daytime sleepiness) are possible. Total scores between 0 and 70 are possible, where higher scores indicate more sleep problems.
Results for this outcome have not been posted.
a 26-item questionnaire for parents to evaluate the burden of care on their quality of life. The parent/caregiver will rate each item as 0 (never), 1 (rarely), 2 (sometimes), 3 (quite frequently), or 4 (nearly always) where higher scores indicate higher severity. Total scores between 0 and 104 are possible, where higher scores indicate more caregiver burden.
Results for this outcome have not been posted.
ketamine EEG alpha, beta, gamma, delta and theta waveform signatures compared to placebo to indicate target engagement
Results for this outcome have not been posted.
Collected over 6 weeks. Non-serious events are listed at a 4.3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.75 mg/kg Ketamine | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| 0.75 mg/kg Placebo | 0/11 (0%) | 0/11 (0%) | 4/11 (36.4%) |
| 1.5 mg/kg Ketamine | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| 1.5 mg/kg Placebo | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Event | 0.75 mg/kg Ketamine | 0.75 mg/kg Placebo | 1.5 mg/kg Ketamine | 1.5 mg/kg Placebo |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/11 | 1/11 | 0/12 | 1/12 |
| VomitingGastrointestinal disorders | 1/11 | 1/11 | 1/12 | 1/12 |
| Tonic convulsionNervous system disorders | 0/11 | 1/11 | 0/12 | 0/12 |
| InsomniaPsychiatric disorders | 0/11 | 1/11 | 0/12 | 0/12 |
| IrritabilityPsychiatric disorders | 0/11 | 1/11 | 1/12 | 0/12 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 1/11 | 0/11 | 0/12 | 0/12 |
| DiarrhoeaGastrointestinal disorders | 0/11 | 0/11 | 1/12 | 0/12 |
| EructationGastrointestinal disorders | 0/11 | 0/11 | 1/12 | 1/12 |
| PyrexiaGeneral disorders | 0/11 | 0/11 | 1/12 | 1/12 |
| Ear infectionInfections and infestations | 0/11 | 0/11 | 1/12 | 0/12 |
| Age, Continuous(years) | All Study Participants - 0.75 mg/kg Ketamine | All Study Participants - 1.5 mg/kg Ketamine | Total |
|---|---|---|---|
| Mean | 8.6 ± 2.20 | 7.6 ± 1.93 | 8.1 ± 2.09 |
| Sex: Female, Male(Participants) | All Study Participants - 0.75 mg/kg Ketamine | All Study Participants - 1.5 mg/kg Ketamine | Total |
|---|---|---|---|
| Female | 11 | 12 | 23 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | All Study Participants - 0.75 mg/kg Ketamine | All Study Participants - 1.5 mg/kg Ketamine | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 11 | 11 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | All Study Participants - 0.75 mg/kg Ketamine | All Study Participants - 1.5 mg/kg Ketamine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 9 | 11 | 20 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | All Study Participants - 0.75 mg/kg Ketamine | All Study Participants - 1.5 mg/kg Ketamine | Total |
|---|---|---|---|
| United States | 11 | 12 | 23 |
| Weight(kg) | All Study Participants - 0.75 mg/kg Ketamine | All Study Participants - 1.5 mg/kg Ketamine | Total |
|---|---|---|---|
| Mean | 24.4 ± 7.33 | 21.5 ± 4.62 | 22.9 ± 6.10 |
| Height(cm) | All Study Participants - 0.75 mg/kg Ketamine | All Study Participants - 1.5 mg/kg Ketamine | Total |
|---|---|---|---|
| Mean | 126.0 ± 11.84 | 117.5 ± 9.41 | 121.7 ± 11.30 |
| BMI(kg/m^2) | All Study Participants - 0.75 mg/kg Ketamine | All Study Participants - 1.5 mg/kg Ketamine | Total |
|---|---|---|---|
| Mean | 15.1 ± 3.06 | 15.4 ± 1.89 | 15.2 ± 2.48 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Nov 2021, 31 months.
Results were first posted in Mar 2024, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ketamine
Rett Syndrome Research Trust